RXi Pharmaceuticals has applied its sd-rxRNA to dermal cells, establishing the efficacy of the technology as it seeks to move it on to the next stage of development, a company VP told in-PharmaTechnologist.
The UK budget was “a missed opportunity” to encourage manufacturing, according to UK Chemical Industries Association (CIA), but was free from unexpected tax increases.
Contract manufacturing organization (CMO) ScinoPharm says strong anticancer API sales and growing demand in Europe and Asia were key to record performance in 2009.
The increasing incidence of chronic and “lifestyle” related disorders will fuel demand for inhalable delivery technologies over the next five years, according to a Global Industry Analysts (GIA) report.
Novozymes Biopharma has published data demonstrating the ability of Recombumin, an excipient, to protect against aggregation, oxidation and non-specific adsorption.
The IPEA's issuance of good manufacturing practice (GMP) “certification” is mark of manufacturing quality, says US specialty chemicals supplier W R Grace & Co.
Dr Reddy’s has made a “significant investment” in an mPEG alcohol production facility in Mexico to strengthen its presence in a sector it believes is on the rise.
The Botswanan government is seeking to initiate local pharma manufacturing, which would lower drug prices, by entering into public-private partnerships (PPP), according to a report by F&S.
Compugen has developed a computer-based, in silico system which can assist drug delivery research by identifying peptides that have the potential to penetrate cell membranes.
US Food and Drug Administration (FDA) request for more Afrezza data is not safety related and will not require new clinical trials, says developer MannKind.
Patheon attributes Q1 loss to charges and plant closure costs and says there has been “an encouraging increase in new sales activity” in calendar 2010.
Drug researchers will have greater access to some top selling molecules, including currently patented compounds atorvastatin, sildenafil and celecoxib, thanks to Sigma Aldrich’s new bioactives deal with US drug major Pfizer.
Merck & Co has joined a coalition to build a vaccine facility which is capable of simultaneously manufacturing multiple products and can quickly switch in response to a crisis.
The Chinese government is supporting a $100m (€73m) project to build a contract biologics production facility in Beijing, which, by some measures, would be the largest in Asia.
DNA sequencing specialist Genewiz has added gene synthesis to its service portfolio, providing researchers with a time- and cost-saving alternative to techniques such as molecular cloning and protein engineering.
Pharmadule AB is creating a complete modular biologics production facility, which will be 80 per cent completed in its workshop before delivery, to Lithuania-based Silcor Biotech by 2011.
Cambridge Major Laboratories (CML), Avantium, Xcelience and Beckloff have formed a consortium to offer tailored, client-focused CMC packages which are particularly suited to atypical compounds.
Xcellerex is using its single use bioreactor system, FlexFactory, to develop a novel manufacturing process for Humacyte’s regenerative medicine candidate.
Indian generic drugmaker Aurobindo Pharma officially launched its CRAMS unit AuroSource last week, also unveiling plans for an R&D facility in Pashamylaram near Hyderabad, India.
Inovio Biomedical has developed a hand-held, cordless electroporation device, Cellectra-SP, which it believes is well suited to administering DNA vaccines in mass immunization programmes.
South Africa-based Aspen Pharma is to sell its Brazilian oral solid dosage form manufacturing facility to Strides Arcolab after posting a 15 per cent drop in revenues from Latin America.
A significant share of contract API maker ScinoPharm Taiwan is set to change hands after Watson Pharmaceuticals decided to sell its stake to Uni-President Enterprises Corporation.
PARI Respiratory Equipment has launched its Vios aerosol delivery system to provide a tool for quickly administering treatments to the lungs, with a small particle size and high respirable drug dose.
US FDA clearance for Italian antibiotics production facility is important for global growth says German contract development and manufacturing organisation (CDMO) Haupt Pharma.
iBio has agreed in principle to license its iBioLaunch platform, which uses Nicotiana to produce therapeutics, to G-Con for the development and manufacture of plant-expressed influenza vaccines.
SAFC Pharma is preparing for the shift towards cell culture-based vaccines, while still supplying and growing in the traditional sector, to ensure it can grow in coming years, according to a company director.
Lek has opened a 430m² modified protein manufacturing facility in Slovenia to produce epoetin alfa drug substance for use in the biosimilars marketed by its parent company, Sandoz.
In the economic downturn biotechs have cut back on outsourcing to Asia and opted to use the US instead because they lack the resources to manage overseas relationships, according to a SOCMA representative.
Aesica is looking to acquire manufacturing assets in the US to expand its client base in the country and continue the growth it has maintained throughout the economic downturn.
The Chinese API sector shrank last year after a number of high profile quality problems hit demand from Western markets, according to new analysis by outsourcing consultant JZ Med.
US group Aptuit has bolstered its chemistry offering with a new solid state chemistry screen that it says will enable better decisions during drug formulation development and process scale-up.
The impact of the economic downturn is still being felt but SAFC remains "cautiously optimistic" about 2010, believing its close relationships with clients and investment in key emerging markets will generate business.
Revenues fell 3 per cent in 2009 at SAFC but pharmaceutical sector demand for vaccine manufacturing products helped firm finish year with six months of growth.
Indian drugmaker Elder Pharmaceuticals says its new manufacturing plant in Dehradun, Uttarakhand State will boost sales 15 per cent and provide capacity for expansion in overseas market.
Rusnano, the group set up to promote Russia’s nanotechnology infrastructure, says nanodrug development partnership will improve patient access and cut cancer death rates across the country.
Cambrex reported a dip in revenues in 2009, citing the timing of orders throughout the year, and warned that smaller clients’ funding difficulties and pricing pressures will continue in 2010.
US biotechnology firm NexBio has received a patent for “pioneering” host cell-targeting influenza drugs that can cut the risk of viral mutation and the emergence of drug resistant strains.
MDRNA’s liposomal drug delivery formulation, DiLA2, lost no potency when stored for 12 months in conditions ranging from -80ºC to 4ºC, helping to validate it for administration of UsiRNA.
ISCO’s stem cell manufacturing facility has passed final building inspection, enabling it to implement the processes and cGMP standards needed to produce clinical-grade products.
In-PharmaTechnologist presents a round up of recent developments in the field of drug delivery, with new deals for Starpharma and Penwest, and a regulatory filing for Hovione.
Full-year income at the Lonza was hit by falling demand for life science ingredients and custom manufacturing services and only modest gains for its bioscience unit.
Crospon has spun out its transdermal controlled release patch into a distinct company, two years after it licensed the system from HP, using funding from a pharma firm to further its development.
Environmental certification of production facilities should be introduced to GMP legislation and sustainability risk assessments linked to marketing authorisations, according to a MPA report.
Merck KGaA has begun work on a new inorganic salts plant in Darmstadt, Germany, citing growing demand as the main motivation for the €30m ($42m) investment.
